A double blind multicentre study of OM-8980 and auranofin in rheumatoid arthritis.
AUTOR(ES)
Vischer, T L
RESUMO
The therapeutic efficacy of the immunomodulator OM-8980 in rheumatoid arthritis was compared with that of auranofin, an oral gold salt, in a double blind, randomised multicentre study lasting six months. Seventy patients were treated with auranofin and 75 with OM-8980. The patients of both groups improved significantly at three and six months for all the clinical parameters observed: Ritchie index, number of swollen joints, morning stiffness, pain, grip strength, intake of non-steroidal anti-inflammatory drugs, and erythrocyte sedimentation rate. No serious side effects were observed in either group. The patients receiving auranofin had more adverse reactions, mainly affecting the gastrointestinal system.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1003574Documentos Relacionados
- Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study.
- Levamisole in rheumatoid arthritis. Final report on a randomised double-blind study comparing a single weekly dose of levamisole with placebo. Multicentre Study Group.
- Azathioprine: a controlled, double-blind trial in rheumatoid arthritis.
- Synthetic d(-)penicillamine in rheumatoid arthritis. Double-blind controlled study of a high and low regimen
- Proceedings: A double-blind comparative trial of cyclophosphamide and gold in rheumatoid arthritis.
